The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15‐year experience in 789 patients treated at a single institution
Abstract
BACKGROUND: The evaluation variables influencing systemic and local recurrence and final outcome are extremely important in defining risk‐adapted treatments for patients with nonmetastatic osteosarcoma of the extremity. METHODS: A homogeneous group of 789 patients treated at a single institution between March 1983 and March 1999 with different protocols of neoadjuvant chemotherapy, with a minimum followup of 5 years, were retrospectively evaluated in relation to gender, age, serum levels of alkaline phosphatase, tumor site and size of the pathologic fracture, type of surgery, protocol of chemotherapy, surgical margins, and histologic response to preoperative treatment. RESULTS: The 5‐year event‐free survival (EFS) and overall survival rates were 60.1% and 67.5%, respectively. Upon univariate analysis, EFS was significantly related to the age of patients, serum value of alkaline phosphatase, tumor volume, histologic subtype, type of surgery, surgical margins, histologic response to preoperative treatment, and chemotherapy protocol. Local recurrences (4.8%) were significantly correlated with surgical margins. The 5‐year postrecurrence EFS survival was 17% and was significantly lower for patients who had a local recurrence and metastases than for those with metastases only. Patients who had a recurrence only in the lung had a postrecurrence survival rate significantly better than others, correlated with the number of metastatic nodules and the length of the disease‐free interval. CONCLUSIONS: Upon multivariate analysis, age ≤ 14 years, high serum levels of alkaline phosphatase, tumor volume > 200 mL, a two‐drug regimen chemotherapy, inadequate surgical margins, and poor histologic response to treatment maintained independent prognostic values on the outcome of nonmetastatic osteosarcoma of the extremities. These factors must be considered when deciding risk‐adapted treatments for osteosarcoma patients. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K., & Mertens, F. (2002) · Lund University Publications (Lund University) · Cited by 4,467
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Pathology and genetics of tumors of soft tissue and bone
Fletcher, C. D. �. (2002) · Medical Entomology and Zoology · Cited by 550
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.76 · Cited by 461
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Bramwell, V. H., Burgers, M., Sneath, R., Souhami, R., van Oosterom, A. T., Voûte, P. A., Rouesse, J., Spooner, D., Craft, A. W., & Somers, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1579 · Cited by 313
Bacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Prever, A. B. D., Gherlinzoni, F., Mercuri, M., & Monti, C. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c · Cited by 294
Self-citationPicci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., Bertoni, F., Guerra, A., Capanna, R., Albisinni, U., et al. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7<1515::aid-cncr2820560707>3.0.co;2-6 · Cited by 274
Self-citationBacci, G., Picci, P., Ruggieri, P., Mercuri, M., Avella, M., Capanna, R., Brach Del Prever, A., Mancini, A., Gherlinzoni, F., Padovani, G., et al. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m · Cited by 235
Self-citationG�bel, V., J�rgens, H., Etsp�ler, G., Kemperdick, H., Jungblut, R. M., Stienen, U., & G�bel, U. (1987) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00391442 · Cited by 233
Saeter, G., Alvegård, T. A., Elomaa, I., Stenwig, A. E., Holmström, T., & Solheim, O. P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1766 · Cited by 225
Neoadjuvant chemotherapy for osteosarcoma of the extremity
Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., & DePaolis, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00229-5 · Cited by 174
Self-citationScandinavian Sarcoma Group Osteosarcoma Study SSG VIII
Smeland, S., Müller, C., Alvegard, T. A., Wiklund, T., Wiebe, T., Björk, O., Stenwig, A. E., Willén, H., Holmström, T., Follerås, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00747-5 · Cited by 166
Bacci, G., Longhi, A., Forni, C., Setola, E., & Ferrari, E. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00546-x · Cited by 155
Self-citationGoorin, A. M., Shuster, J. J., Baker, A., Horowitz, M. E., Meyer, W. H., & Link, M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.600 · Cited by 134
Goorin, A. M., Pérez‐Atayde, A. R., Gebhardt, M. C., Andersen, J. W., Wilkinson, R. H., Delorey, M. J., Watts, H. G., Link, M. P., Jaffe, N., & Frei, E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1178 · Cited by 125
Bacci, G., Ferrari, S., Longhi, A., Perin, S., Forni, C., Fabbri, N., Salducca, N., Versari, M., & Smith, K. V. J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00361-0 · Cited by 118
Self-citationBacci, G., Ferrari, S., Longhi, A., Picci, P., Mercuri, M., Alvegård, T. A., Sæter, G., Donati, D. M., Manfrini, M., Lari, S., et al. (2002) · Journal of Chemotherapy · doi:10.1179/joc.2002.14.2.198 · Cited by 109
Self-citationOsteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy.
Jaffe, N., Smith, E. F., Abelson, H. T., et al. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.4.251 · Cited by 88
Ferrari, S., Mercuri, M., Picci, P., Bertoni, F., del Prever, A. B., Tienghi, A., Mancini, A. F., Longhi, A., Rimondini, S., Donati, D. M., et al. (1999) · Tumori Journal · doi:10.1177/030089169908500607 · Cited by 79
Self-citationKrailo, M., Ertel, I. J., Makley, J. T., Fryer, C. J., Baum, E. S., Weetman, R. M., Yunis, E. J., Barnes, L. E., Bleyer, W. A., & Hammond, G. D. (1987) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950150205 · Cited by 75
Kalifa, C., Razafindrakoto, H., Vassal, G., Contesso, G., Vanel, D., Edeline, V., Valteau‐Couanet, D., & Lemerle, J. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3518-8_42 · Cited by 24
Cited by
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Dual AO/EB Staining to Detect Apoptosis in Osteosarcoma Cells Compared with Flow Cytometry
Liu, K., Liu, P.-C., Liu, R., & Wu, X. (2015) · Medical Science Monitor Basic Research · doi:10.12659/msmbr.893327 · Cited by 770
Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Metadata
- Authors
- Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-01-18
- Volume
- 106
- Issue
- 5
- Pages
- 1154-1161
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2098002569
- Cited by
- 569
- References
- 25
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.